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Pseudomonas aeruginosa is the predominant pathogen in pulmonary infections
associated with cystic fibrosis. Quorum sensing (QS) systems regulate the production
of virulence factors and play an important role in the establishment of successful
P. aeruginosa infections. Inhibition of the QS system (termed quorum quenching) renders
the bacteria avirulent thus serving as an alternative approach in the development of
novel antibiotics. Quorum quenching in Gram negative bacteria can be achieved by
preventing the accumulation of N-acyl homoserine lactone (AHL) signaling molecule via
enzymatic degradation. Previous work by us has shown that PvdQ acylase hydrolyzes
AHL signaling molecules irreversibly, thereby inhibiting QS in P. aeruginosa in vitro and in
a Caenorhabditis elegans model of P. aeruginosa infection. The aim of the present study
is to assess the therapeutic efficacy of intranasally instilled PvdQ acylase in a mouse
model of pulmonary P. aeruginosa infection. First, we evaluated the deposition pattern
of intranasally administered fluorochrome-tagged PvdQ (PvdQ-VT) in mice at different
stages of pulmonary infection by in vivo imaging studies. Following intranasal instillation,
PvdQ-VT could be traced in all lung lobes with 42 ± 7.5% of the delivered dose being
deposited at 0 h post-bacterial-infection, and 34 ± 5.2% at 72 h post bacterial-infection.
We then treated mice with PvdQ during lethal P. aeruginosa pulmonary infection and
that resulted in a 5-fold reduction of lung bacterial load and a prolonged survival of
the infected animals with the median survival time of 57 hin comparison to 42 h for the
PBS-treated group. In a sublethal P. aeruginosa pulmonary infection, PvdQ treatment
resulted in less lung inflammation as well as decrease of CXCL2 and TNF-α levels at 24 h
post-bacterial-infection by 15 and 20%, respectively. In conclusion, our study has shown
therapeutic efficacy of PvdQ acylase as a quorum quenching agent during P. aeruginosa
infection.
Keywords: Pseudomonas aeruginosa, PvdQ acylase, quorum sensing, quorum quenching, mouse model,
pulmonary infection
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INTRODUCTION
Pseudomonas aeruginosa is an opportunistic Gram negative
bacterium that is mainly associated with hospital-acquired
infections and known as the major pathogen in cystic fibrosis
(CF) patients (Driscoll et al., 2007). Nearly all pulmonary
P. aeruginosa infections in CF patients will develop into chronic,
persistent infections that require aggressive antibiotic treatments
(Van Delden and Iglewski, 1998). The intrinsic traits of this
bacterium coupled with complex adaptive behaviors such as
biofilm formation make it resilient to many antibiotic treatments
(Breidenstein et al., 2011). All of these elements propelled
P. aeruginosa into a significant multidrug-resistant pathogen
worldwide.
In numerous pathogens, production of bacterial virulence
determinants is tightly regulated in a cell density-dependent
manner, aided by a quorum sensing (QS) signaling system
(Fuqua and Greenberg, 2002). By detecting the accumulation
of signal molecules, each individual cell is capable of sensing
the population density and subsequently responds by producing
an arsenal of virulence factors when a critical population mass
is reached (Cámara et al., 2002). The most studied signaling
molecules in Gram-negative bacteria are N-acyl homoserine
lactones (AHLs) (Papenfort and Bassler, 2016). The AHLs are
produced by AHL-synthases (e.g., LuxI-type family) and sensed
by transcriptional regulators (LuxR-type family) (Fuqua and
Greenberg, 2002). The core of QS in P. aeruginosa consists of
two LuxRI-based signaling systems that work in a hierarchal
fashion, namely LasRI and RhlRI with 3-oxo-C12-HSL and C4-
HSL as their respective cognate AHL (Jimenez et al., 2012).
Deletion of either the AHL synthases or AHL receptors resulted
in a downregulation of QS-regulated virulence factors, such
as rhamnolipids, elastase protease, pyocyanin siderophore, and
biofilm formation (Passador et al., 1993; Whiteley et al., 1999).
These QS mutants are less pathogenic in animal models in
comparison to the wild-type (Wu et al., 2001; Imamura et al.,
2005), revealing the importance of this system for establishing
successful infections. These findings opened up a possibility of
attacking QS system as a new antivirulence drug therapy.
Quorum sensing (QS) inhibition (termed quorum quenching,
QQ) can be performed by employing small molecule inhibitors to
block the AHL productions or to avoid the interaction between
AHLs and the response regulators. Bioactive compounds isolated
from natural sources, or ones that are synthetized chemically,
have shown therapeutic efficacy as QS inhibitors (QSIs) both
in vitro and in vivo (Hentzer et al., 2002; Bjarnsholt et al.,
2005; Rasmussen et al., 2005; Jakobsen et al., 2012a,b). However,
some well-known small molecules inhibitors (QSIs), such as
patulin and furanones, are toxic for mammals (Hentzer and
Givskov, 2003; Puel et al., 2010) diminishing their potential
for use humans. Another obvious approach for QS inhibition
is by preventing accumulation of signal molecules by means
of enzymatic degradation (Kalia, 2013). So far, three classes
of enzymes have been identified that are known to inactivate
AHLs, namely (i) AHL-lactonases [that cleave the ester bond in
the homoserine lactone (HSL) ring moiety; Dong et al., 2000;
Wang et al., 2010], (ii) AHL-acylases (that irreversibly hydrolyze
the amide bond between the acyl chain and HSL; LaSarre and
Federle, 2013), and the least studied (iii) AHL-oxidoreductases
(that modify the 3-oxo-substituents of the AHLs; Uroz et al.,
2005).
Numerous AHL-inactivating enzymes (QQ enzymes) were
characterized, but only lactonase has been tested for its efficacy
in mammalian models of pulmonary infection (Migiyama et al.,
2013; Hraiech et al., 2014). Due to the large size of the
enzyme molecules, the only possible route of administration
is via the upper respiratory tract. Combining the procedures
of establishing the infection and delivering the drug via the
upper respiratory tract is challenging to be performed in small
animals. Therefore, the recent study on the administration of an
AHL-lactonase was done in rats using intubation of trachea. It
successfully reduced mortality in the rat model of pneumonia
(Hraiech et al., 2014). However, there is yet no study that employs
a non-invasive drug administration method that closely mimics
the actual procedure in human.
The purpose of our study was to determine the efficacy of
one of the other AHL-inactivating enzymes, an AHL-acylase
that was instilled intranasally in a mouse model of pulmonary
P. aeruginosa infection. Our enzyme of interest is PvdQ acylase,
a periplasmic enzyme from P. aeruginosa that is suggested
to be involved in the maturation of pyoverdine siderophore
(Drake and Gulick, 2011). Beside this function, PvdQ is a well-
studied AHL-hydrolyzing enzyme, with specificity to long chain
AHLs (Sio et al., 2006; Bokhove et al., 2010). PvdQ, either
overexpressed in, or exogenously supplemented to P. aeruginosa,
could significantly attenuate the virulence production, both
in vitro (Sio et al., 2006), and in vivo in a Caenorhabditis elegans
model (Papaioannou et al., 2009). In this report, we show results
of PvdQ acylase deposition in the respiratory tract after intranasal
administration and its efficacy in lethal and sublethal models of
pulmonary P. aeruginosa infection.
MATERIALS AND METHODS
Bacterial Strains and Growing Condition
Enzymatic hydrolysis of long chain AHL was monitored by
employing a reporter strain E. coli pSB1075 (AmpR) (Winson
et al., 1998). Determination of PvdQ inhibition strength was
performed by reporter strains P. aeruginosa PlasB::lux (Koch
et al., 2014) and PrhlA::lux (TetR) (this study). P. aeruginosa
PAO1 was obtained from Barbara Iglewski (University of
Rochester Medical Center, Rochester, NY) (Sio et al., 2006).
The overnight cultures of the biosensors were prepared by
inoculating a loop of frozen glycerol stock in Luria Bertani (LB)
medium, followed by incubation at 37◦C, 200 rpm. For the
animal experiments, P. aeruginosa PAO1 from a frozen glycerol
stock was grown in Pseudomonas isolation agar (PIA) selection
medium (BD DifcoTM) overnight at 37◦C. A single colony was
used to inoculate a 100mL LB medium in a 250mL erlenmeyer
flask, at 37◦C, 200 rpm for 18 h. When necessary, 100 µL/mL
tetracycline or 50 µL/mL ampicillin was added to the media.
Preparation of PvdQ
Production and Purification of PvdQ
PvdQ was produced and purified as reported previously
(Bokhove et al., 2010), with modifications. E. coli DH10B
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harboring pMCT_pvdQ was grown in 2xTY medium with
chloramphenicol supplementation (50µg/mL) for 30 h at
30◦C, 200 rpm. The harvested cells were sonicated in a
three times volume of lysis buffer (50mM Tris Cl pH 8.8;
2mM EDTA), followed by centrifugation at 17.000 rpm
for 1 h. The clear lysate was applied to an anion exchange
HiTrap Q-sepharose column and the flowthrough containing
PvdQ was collected. After adjusting the ammonium sulfate
concentration to 750mM, the solution containing PvdQ was
applied to a phenyl sepharose column. PvdQ eluted at the end
of the 1,000–0mM ammonium sulfate gradient. The buffer
was exchanged into 50mM sodium phosphate pH 6.5 and
the sample was applied to a HiTrap Q-sepharose column.
The collected flowthrough was subsequently concentrated
and applied to a gel filtration superdex 16/60 75. A major
peak containing PvdQ was collected, snap frozen and stored
at −80◦C until further use. All protein chromatography
columns were obtained from GE Healthcare Life
Sciences.
Endotoxin Removal From the Purified PvdQ
For animal experiments, endotoxin contamination in purified
PvdQ was eliminated using a PierceTM High Capacity Endotoxin
Removal Resin (Thermo Scientific) following the manufacturer’s
manual. To adjust the PvdQ concentration, an endotoxin-free
PBS buffer (Millipore, Merck) was used. The endotoxin content
of purified PvdQwas analyzed with the LAL test at the University
Medical Center Groningen, the Netherlands.
Fluorochrome Labeling of PvdQ
For the purpose of the PvdQ deposition study in mice,
PvdQ was labeled with VivoTag 680 XL Fluorochrome (Perkin
Elmers). 0.5mg PvdQ (1 mg/mL) was labeled according to the
manufacturer’s manual. The calculated degree of labeling was 2,
indicating that in average 2 dye molecules were coupled to one
molecule of PvdQ.
In Vitro Quorum Quenching Activity of
PvdQ
Enzymatic Activity of PvdQ in Hydrolyzing
3-oxo-C12-HSL
The enzymatic activity of PvdQ in deacylating 3-oxo-C12-HSL
(Cayman Chemical) was validated using a bioassay procedure
as previously described (Wahjudi et al., 2011). E. coli JM109
(pSB1075) biosensor that emits luminescence in the presence
of long-chain AHLs was employed to detect the remaining
3-oxo-C12-HSL. Briefly, 2 µL of 0.5 mg/mL 3-oxo-C12-HSL
in acetonitrile was spotted onto a flat-bottom µClear white
microplate (Greiner Bio-One) and incubated at the room
temperature until the acetonitrile evaporated. The remaining
AHL was solubilized in 100 µL PBS buffer pH 7.4 containing
5 µg of PvdQ. A control reaction was prepared in identical
conditions using heat-inactivated PvdQ. After 4 h at 30◦C with
slow agitation, 100 µL of the 100 times diluted overnight
biosensor was added to each well. The emitted luminescence
and the bacterial growth (OD600) were monitored in a FLUOstar
Omega platereader (BMG Labtech).
Quorum Quenching Activity of PvdQ in P. aeruginosa
Reporter Strains
The following assays were performed to determine the quorum
sensing inhibition activity of PvdQ by employing P. aeruginosa
biosensors. P. aeruginosa PrhlA::lux and PlasB::lux each
containing a chromosomal insertion of a luciferase gene under
the control of a rhlA rhamnolipid promoter or a lasB elastase
promoter, respectively (Koch et al., 2014). Two-fold serial
dilutions of PvdQ in PBS (100 µL) were made in a flat-bottom
µClear white microplate (Greiner Bio-One), covering PvdQ
concentration of 0–16µM. Overnight cultures of the biosensors
were diluted 100 times in LB, and 100 µL was added to the
wells containing PvdQ. The emitted luminescence and the
bacterial growth (OD600) were monitored in a FLUOstar Omega
platereader (BMG Labtech).
Epithelial Cell Viability Assay
The effect of PvdQ on the cell viability was assessed in the lung
epithelial cell lines A549 and H460. Serial 2-fold dilutions of
PvdQ with a maximum concentration of 10µM were added to
105 cells, followed by incubation at 37◦C for 48 h. The level of cell
proliferation was determined by a 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS salt, Promega) proliferation assay according to the
manufacturer’s manual.
Preparation of the Agarose-Embedded
Bacteria
One day prior to infection of animals, P. aeruginosa PAO1 was
embedded in agarose as explained elsewhere (van Heeckeren
and Schluchter, 2002; Kukavica-Ibrulj et al., 2014), with
modifications. Cell pellets from 100mL overnight culture of
P. aeruginosa PAO1 were washed twice with a sterile PBS, and
were resuspended in 5mL LB. A volume of 1mL bacterial
suspension was added to 10mL 1.5% sterilized, pre-warmed (48–
50◦C) agarose (Type I Low EEO, Sigma-Aldrich) and mixed
thoroughly. To prepare sterile agarose beads, a sterile LBmedium
was added to the agarose solution. The mixture was pipetted
dropwise into the center of stirred vegetable oil (200mL) that
was equilibrated at ∼50◦C. The stirring was kept at 1500 rpm
for 6min at ∼50◦C. Afterwards, the emulsion was stirred slowly
at 4◦C for 20min, followed by incubation on ice for 20min.
100mL oil in the top layer was discarded, and the remaining
agarose beads were washed with PBS, followed by centrifugation
in a swinging bucket rotor at 2,700 × g, 4◦C for 15min. The
beads were subsequently washed one time with 0.5% sodium
deoxycholic acid (SDC, Sigma-Aldrich) in PBS, one time with
0.25% SDC, and 4 times with PBS. After the last wash, PBS was
added to the agar beads in a ratio of 2:1. The agarose beads slurry
was stored at 4◦C prior to use the following day. A homogenized
aliquot of the agarose beads was serially diluted and plated onto
PIA medium, followed by incubation at 37◦C for 24 h. Based
on the counted colony forming unit (CFU) on PIA plates, the
original agarose beads slurry was adjusted with PBS to 1.25× 107
CFU/mL (lethal dose) or 6.25 × 106 CFU/mL (sublethal dose)
and 40 µL of the bacterial preparation was administered per
animal.
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Animal Experiments
Animal experiments were conducted in accordance with the
Dutch Animal Protection Act and were approved by the
Netherlands National Committee for the protection of animals
used for scientific purposes (DEC6692, AVD105002017854).
The experiments were performed in a BSL-2 area in the
Central Animal Facility (CDP) of the University Medical Center
Groningen (UMCG). Female BALB/c mice aged 11–12 weeks old
with a minimum weight of 20 grams (at the start of experiment)
were purchased from Charles River, France. Groups of 4–6 mice
were housed in individual ventilator cages with unrestricted
access to food and water. Infected animals were placed in cages
with warming pads at the bottom of the cage.
Infection Procedure and Intranasal PvdQ
Administration
The procedure for developing pulmonary infection in our study
was a combination between intratracheal instillation of bacteria
at the start of the experiment, and a daily intranasal delivery of
the drug.
Intratracheal Instillation of Bacteria
Sterile agarose beads or agarose beads laden with P. aeruginosa
PAO1 were instilled into the lungs via nonsurgical intratracheal
administration (Bivas-Benita et al., 2005; Munder and Tümmler,
2014). Mice were anesthetized by isoflurane inhalation and the
depth of anesthesia was checked by the foot reflex toward
pinching. Mice were then placed vertically by the upper teeth
on an intubation stand, with continuous anesthesia through a
nose cone. Cold light was placed in front of the throat and the
tongue was retracted to the side using forceps. When the trachea
was visualized, a disposable sterile intravenous G20 catheter (BD
Insyte-W) with an adjusted length was inserted into the trachea.
To confirm that the catheter was indeed inside the trachea, a
ventilator (Harvard Minivent) was connected. Correct catheter
placement will show the chest, but not the abdomen, moving
in synch with the ventilator’s programmed rate. Afterwards,
40 µL of agarose beads were carefully administered into the
catheter, followed by blowing 200–400 µL of air into the
catheter to ensure that all beads were delivered into the lungs.
While the animal was still under anesthesia, a transponder
microchip (IPTT-300, BMDS) for temperature measurement
was implanted subcutaneously. This transponder allows body
temperature measurement with a portable reader device (DAS-
7006s, BMDS) by scanning the mice without direct contact.
The mice were weighed daily and their general appearance
(body temperature, coat condition, behavior and locomotion)
was monitored 2–3 times a day. At designated time points,
the mice were anesthetized with isoflurane and euthanized
by cardiac exsanguination. Blood, bronchoalveolar lavage fluid,
kidney, spleen, and lungs were collected aseptically from the
animals.
Intranasal PvdQ Administration
Mice were lightly anesthetized with isoflurane and held in a∼60◦
inclined supine position. Subsequently, 50 µL PvdQ was instilled
dropwise onto the nose of the anesthetized animal. The control
group (PBS-treated) received an intranasal administration of
50µL PBS.
Study Design
The in vivo study consisted of three parts: Study 1. Mouse
tolerance of PvdQ; Study 2. In vivo imaging to monitor
deposition of intranasally administered PvdQ; Study 3. An
efficacy study of PvdQ in a mouse pulmonary infection model.
Study 1. Mouse Tolerance of the Intranasally
Administered PvdQ
To determine tolerance of PvdQ, groups of mice were
intratracheally challenged with sterile agarose beads and received
a daily intranasal administration of PvdQ (25 and 250 ng/g
body weight) or PBS. Animals from each group was sacrificed
at 24, 48, or 72 h after the first intranasal administration for
analysis of immune responses or inflammation. Experiments
were performed in duplicate, totaling to 4 animals per group.
Study 2. In Vivo Imaging to Monitor Deposition of
Intranasally Administered PvdQ
As PvdQ is a protein, special attention was given to proper
delivery to the location of infection, i.e., the lungs. Deposition
of intranasally administered PvdQ in airways of mice was
examined by employing a VivoTag 680XL-labeled PvdQ (PvdQ-
VT). Groups of animals were infected with a sublethal dose of
P. aeruginosa PAO1 and received 50 µL of 1 mg/mL PvdQ-VT
intranasally at 0 and 72 h post-bacterial inoculation. The animals
were allowed to recover for 5min after PvdQ-VT administration,
followed by in vivo imaging as previously described (Tonnis
et al., 2014). First, the animal was placed in a Fluorescence
Molecular Tomography (FMT, PerkinElmer, Waltham, USA)
that permits localization of PvdQ-VT in a three-dimensional
visual of the animal. The fluorescence was measured at an
excitation wavelength of 660 nm and an emission wavelength
of 680 nm. Next, the animal was sacrificed and the isolated
lungs were placed on a petri dish, followed by visualization in
the In Vivo Imaging System (IVIS R© Spectrum, PerkinElmer,
Waltham, USA). The fluorescence was measured at an excitation
wavelength of 675 nm and an emission wavelength of 720 nm.
The acquired data from FMT and IVIS were analyzed by
TrueQuantTM v3.1 software and Living Image R© Software v3.2,
respectively. The relative deposition of PvdQ-VT in a certain
region of interest was calculated by dividing the fluorescence
intensity in the region of interest by intensity of the total area
times 100%. Experiments were performed in duplicate, totaling
to 6 animals per group.
Study 3. Efficacy of PvdQ in a Mouse Pulmonary
Infection Model
The efficacy of PvdQ as a quorum sensing inhibitor was assessed
in a lethal (n = 6 per group) and a sublethal pulmonary
infections with P. aeruginosa PAO1. Groups of infected animals
received a daily intranasal administration of PvdQ (25 ng/g
and 250 ng/g body weight) starting immediately after bacterial
inoculation. At 24 and 48 h, mice were sacrificed for quantitative
analysis of bacteriology, immune responses and histopathological
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 4 April 2018 | Volume 8 | Article 119
Utari et al. Quorum Quenching in P. aeruginosa Lung Infection
analysis, unless otherwise stated. Efficacy test in the lethal
infection was performed as one experiment (n = 6 per group),
while experiments for the sublethal infection were performed in
triplicate, totaling to 22–23 animals per group.
Analysis of Animal Samples
Bronchoalveolar Lavage
For bronchoalveolar lavage (BAL), the lungs were flushed three
times with a total volume of 2mL PBS supplemented with
protease inhibitor (cOmpleteTM, EDTA-free Protease Inhibitor
Cocktail, Roche). Cytospin preparations from 100 µL of
unprocessed BAL fluid sample were stained with May Grünwald
and Giemsa staining for differential cell counts. Levels of TNF-α
and CXCL2 in the cell-free supernatant of BAL fluid (600 rpm
slow acceleration, room temperature for 5min) were measured
by ELISA in accordance to the manufacturer’s instructions
(Duoset, R&D systems).
Quantitative Bacteriology
Isolated lungs were homogenized in 5mL PBS using amechanical
homogenizer (IKA-RW15 potter system). Blood, BAL fluid and
serial dilution of lung homogenates were plated on the selective
media Pseudomonas Isolation Agar (PIA) for quantitative
bacteriology.
Histopathology
Lungs were inflated with cryocompound (Klinipath) and fixed
in 4% formaldehyde (Sigma-Aldrich) overnight. Afterwards, the
lobes were separated and trimmed prior to paraffin-embedding
(Ruehl-Fehlert et al., 2004). Sections of 3–4µm were stained
with haematoxylin and eosin (Sigma-Aldrich). 10–15 areas of the
lung sections were scored blindly for peribronchial infiltrates and
alveolar involvement at a 40x magnification using an adapted
histological scoring system (Table 1; Bayes et al., 2016) that was
originally mentioned in Dubin et al. (Dubin and Kolls, 2007).
Statistical Analysis
Comparisons between two groups were carried out using Mann
Whitney U (non-parametric data). Survival graph was created
using the method of Kaplan-Meier, and the comparison of
survival between groups was analyzed by the χ2-test. Statistical
analysis was performed using Graphpad Prism version 5 or
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SPSS statistics version 25. A probability value (P) ≤ 0.05 was
considered statistically significant.
RESULTS
In Vitro Study of PvdQ
Purified PvdQ Is Active and Quenches the Virulence
of P. aeruginosa Biosensors in a Dose-Dependent
Manner
PvdQ was purified with a yield of 30mg L−1 of cell culture.
The protein was >95% pure judged from SDS PAGE with
a Coomassie blue staining (Supplementary Figure 1). Purified
PvdQ for animal experiments underwent an endotoxin removal
step, resulting in a final endotoxin level of 1.6 EU/mg
PvdQ, well below the recommended limit for endotoxin in
preclinical research (Maylyala and Singh, 2008). The endotoxin
removal procedure did not affect the AHL-hydrolyzing activity
of PvdQ (Supplementary Figure 2), as shown by the equal
degradation of 3-oxo-C12-HSL substrate in both enzymatic
reactions.
Effectivity of PvdQ in attenuating virulence of P. aeruginosa
was monitored by employing biosensors with a chromosomal
integration of a luciferase gene controlled by the QS-regulated
lasB promoter or rhlA promoter. Emitted luminescence reflects
activation of the quorum sensing system, thus the amount of
produced light is inversely proportional to the inhibitory strength
of PvdQ. The chosen PvdQ doses did not affect growth of the
biosensors. Dose-response curves were created by plotting the
response of the biosensors as a relative luminescence unit per
cell density (Figure 1). The IC50 value could not be calculated
since complete signal abolishment was not reached. We could
not test a higher concentration of PvdQ to reach a greater signal
reduction, because PvdQ precipitates at concentrations above
4 mg/mL.
Purified PvdQ Does Not Affect the Viability of
Epithelial Cell Lines
The toxicity of PvdQ to mammalian cells was assessed in vitro,
using A549 and H460 human epithelial cell lines. Incubation
of cells with up to 10µM PvdQ for 48 h did not affect
the number of viable cells in comparison to control without
PvdQ treatment (Supplementary Figure 3), suggesting that
PvdQ exhibits minimal to no cytotoxicity toward epithelial
cells.
Validation of the Animal Model and PvdQ
Administration Procedure
The Mouse Infection Model
In principle, the severity of infection in the model depends on the
bacterial inoculation dose and the stress level experienced by the
animals. In our procedure, the infected animals were receiving a
daily administration of PvdQ via intranasal route. Based on pilot
experiments, we found that an inoculation dose lower than 105
CFU/lungs resulted in no development of infection, whereas an
inoculation dose of 106 CFU/lungs resulted in a severe infection.
For the present study we therefore adjusted the inoculation dose
to 2.5 × 105 CFU/lungs as a sublethal dose and to twice that
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FIGURE 1 | Dose-response curve of PvdQ acylase. Biosensors (A) P. aeruginosa rhlA::lux and (B) P. aeruginosa lasB::lux were incubated with various concentration
of PvdQ, as follows: 16µM (), 8µM (), 4µM (N), 2µM (H), 1µM (), 0.5µM (©), 0.25µM (), and 0µM (×).
amount (5 × 105 CFU/lungs) as a lethal dose. Due to the high
discomfort in the lethal infection, the PvdQ distribution study
was only performed in the sublethal infection model, while the
efficacy of PvdQ was investigated in both levels of infections.
Study 1. Mouse Tolerance of Intranasally
Administered PvdQ
Our studies with mammalian epithelial showed that PvdQ was
not toxic to these cells in vitro. Based on these results we
performed the first part of an in vivo study to further ensure
safety of intranasally administered PvdQ in mice. Tolerance
of non-infected mice to intranasally administered PvdQ was
determined with 2 doses of PvdQ (25 and 250 ng/g per animal).
Both doses did not induce breathing difficulties, inactivity, poor
posture or a drop of body temperature. Mild fluctuations of
body weight were observed, with an average of 4% increase or
decrease from the initial body weight, which was comparable to
the control group receiving sterile beads and a daily intranasal
PBS administration. Lungs harvested at 24, 48, and 72 h after
the first PvdQ administration showed no macroscopic injury.
Histological examination of lungs 72 h after PvdQ administration
showed no inflammatory lesions or abnormalities (data not
shown).
Study 2. In Vivo Imaging to Monitor the Deposition of
Intranasally Administered PvdQ
A fluorochrome-tagged PvdQ (PvdQ-VT) was used to ascertain
the deposition of the intranasally administered PvdQ-VT in
mouse lung tissue. To determine whether infection influences
enzyme deposition, PvdQ-VT was intranasally administered
to infected animals at different stages of infection (0 and
72 h post-infection) followed by in vivo imaging analyses. The
Fluorescence Molecular Tomography (FMT) allows a three-
dimensional visualization of the whole animal and the typical
result is shown in Figure 2A. PvdQ-VT could be traced along the
respiratory tract of the animals and 42 ± 7.5% of the delivered
dose was deposited in the lungs at 0 h post-infection. At 72 h
post-infection, a slightly lower lung deposition was observed (34
± 5.2%, n.s. compared to 0 h post-infection), and the majority
of PvdQ-VT was found in the upper respiratory tract and the
head. Afterwards, the lungs were isolated for a more thorough
visualization in the In Vivo Imaging System (IVIS) and typical
data are shown in Figure 2B. PvdQ-VT can be found in all lung
lobes with a nearly equal distribution between the right lobes
(combined, 47 ± 10.7%) and the left lobe (53 ± 10.7%) at 0 h
post-infection. However, at 72 h post-infection, the distribution
was shifted with the left lobe containing slightlymore (60± 8.8%)
than the right lobes (40± 8.7%).
Efficacy of PvdQ in a Mouse Model of
Pulmonary Infection
Study 3. (i) Treatment With PvdQ Results in a Longer
Survival Time and Higher Bacterial Clearance During
Lethal Pulmonary Infection
Having established a pulmonary infection model and the safety
of the PvdQ treatment, the next step was to investigate efficacy
of PvdQ treatment in this infection model. Treatment of lethally
infected animals with PvdQ (25 ng/g) resulted in a 5-fold lower
bacterial load for the PvdQ-treated groups than for the PBS-
treated group at the end of experiment (P = 0.0465, Figure 3A).
Furthermore, the PvdQ treatment significantly prolonged the
survival time, with a median survival time of 57 h as compared
to 42 h in the PBS-treated animals (P = 0.004, Figure 3B). The
same extent of efficacy was observed with the treatment of 250
ng/g PvdQ (data not shown).
Study 3. (ii) PvdQ Treatment Results in Less Lung
Inflammation in a Model of Sublethal Pulmonary
Infection
Inoculation with a sublethal bacterial dose resulted in a
moderately severe infection, with no mortality as a consequence.
Using this model, the efficacy of PvdQ treatment was assessed
within 48 h post-infection by performing multiple analyses,
including quantitative bacteriology, analyses of immune
responses and histopathological analysis.
No significant differences were observed in bacterial load
between the PvdQ-treated group and the PBS-treated group at
24 or 48 h post-bacterial-infection (Supplementary Figure 4). No
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FIGURE 2 | Typical imaging results of animals after intranasal administration of PBS (control, left panel) or PvdQ-VT at different stages of infection (middle and right
panels). (A) Results from FMT; (B) Results from IVIS. Upper panels show intact lungs, while lower panels show trachea and the separated lobes. Legend: Trachea (T),
left lung (LL), post-caval lobe (PL), inferior lobe (IL), middle lobe (ML), and superior lobe (SL).
bacteria were found in the blood, spleen or kidney, indicating
that the infection was restricted to the lungs. Histopathological
analysis of lung tissue showed milder inflammation in the
PvdQ-treated group than in the PBS-treated group 24 and 48 h
post-infection (Figure 4). Lung tissue of mice treated with PBS
showed a higher level of lung injury with diffuse inflammation
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FIGURE 3 | Effects of PvdQ treatment in a lethal P. aeruginosa infection mouse model (n = 6 animals). (A) PvdQ treatment results in a lower load of P. aeruginosa in
infected animals as compared to PBS-treatment. The bacterial count was obtained 42–60 h post-bacterial-infection. The box and whiskers respectively represent
25–75th percentiles, and range of the data. The horizontal lines represent the median. (B) PvdQ-treated animals have a significantly longer survival time than
PBS-treated animals.
FIGURE 4 | Lung histology scores of lungs of mice treated with PBS () or
PvdQ () at 24 and 48 h post bacterial-infection in a model of sublethal
pulmonary infection with P. aeruginosa. Three animals were sacrificed from
each group at each time point. The graph represents mean and standard
deviation.
and swollen alveolar walls, while mice treated with PvdQ showed
only small restricted lesions and hardly any alveolar involvement
(Figure 5). In line with this finding, the levels of CXCL2 and
TNF-α in BAL fluid of PvdQ-treated mice were significantly
lower compared to PBS-treated mice at 24 h post-infection. At
48 h post-infection the levels of immune response indicators
were similar between both groups and almost back to the levels
found in non-infected animals (Figure 6). The total number of
inflammatory cells in BAL fluid of PvdQ and PBS-treated animals
was higher as compared to non-infected animals (Supplementary
Figure 5A), but no differences were seen between PBS- and
PvdQ-treated animals. In addition, the number of neutrophils
in BAL fluid was assessed, but again no differences were seen
between PBS and PvdQ treatment (Supplementary Figure 5B).
The same extent of efficacy was observed with the treatment of
250 ng/g PvdQ (data not shown).
DISCUSSION
Pseudomonas aeruginosa infection is a growing problem in
the healthcare, as well as being the predominant pathogen
in pulmonary infections of cystic fibrosis patients. Multiple
factors are contributing to the tenacity of P. aeruginosa as
a human pathogen, including its remarkable adaptability that
allows this bacterium to establish a successful infection and
to escape antibiotic treatments. In the wake of the antibiotic
resistance problem, relatively much attention has been given
to the study of quorum sensing inhibitors (QSIs) as novel
antibacterial candidates (Kalia, 2013; LaSarre and Federle, 2013;
Fetzner, 2014). They fall into the category of antivirulence
drugs that generate less selective pressure for evoking resistance
in comparison to conventional antibiotics. AHL-hydrolyzing
enzymes prevent accumulation of AHLs and the QQ effects
by some of these enzymes are evident in infection models.
Nevertheless, the number of the documented studies inmammals
is relatively small, given the abundance of the characterized
QQ enzymes. The first study in a pulmonary infection model
was conducted by Migiyama and colleagues, showing that
a P. aeruginosa strain overexpressing AiiM lactonase is less
virulent than the wild-type (Migiyama et al., 2013). This finding
was followed by a report from Hraiech and colleagues who
employed a purified SsoPox-I lactonase as a therapeutic agent
in a lethal P. aeruginosa pulmonary infection model in rats
(Hraiech et al., 2014). The purified SsoPox-I lactonase was
administered through the intubation of the exposed trachea and
could reduce the mortality of the infected animals. Although
these studies excellently demonstrated the therapeutic value of
AHL-hydrolyzing enzymes, there is yet no study using a non-
invasive administration route of the enzymes that closely mimics
the possible drug administration route in human. In the present
study, we have shown that PvdQ is well-tolerated by human
lung epithelial cell lines, indicating that PvdQ has minimal or
no cytotoxic effects on human cells. Furthermore, intranasally
administered PvdQ acylase is well-tolerated and distributes well
in lung tissue of mice, even during infection. Most importantly,
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FIGURE 5 | Histological examination of lung tissue of animals infected by sublethal P. aeruginosa dose and treated with either PBS or PvdQ at 48 h
post-bacterial-infection. Upper panels represent images of H&E stainings at 20x magnification, and the areas marked with rectangular are shown in 200x
magnification in the lower panels.
intranasally administered PvdQ acylase alleviates P. aeruginosa
pulmonary infection in mice, which may lead to faster resolution
of the infection.
Prior studies have confirmed that supplementation of PvdQ
to cultures of P. aeruginosa inhibits accumulation of 3-oxo-C12-
HSL and in turn blocks production of elastase and pyocyanin
(Sio et al., 2006). Furthermore, PvdQ showed a therapeutic effect
in a C. elegans model of P. aeruginosa infection (Papaioannou
et al., 2009). In order to test the preclinical efficacy of PvdQ
in a more relevant animal model, we developed a mouse
model combining the P. aeruginosa pulmonary infection with an
administration procedure that can be translated to the human
situation. A pulmonary infection model is very challenging
to be developed in mouse (van Heeckeren and Schluchter,
2002), even more so when the infection is combined with
a topical drug administration method. Lung-targeted delivery
systems of large molecules in animal can be performed via
pulmonary inhalation by different procedures, such as passive
inhalation of aerosolized drugs (whole body, head-only, or
nose-only exposure system), direct intratracheal administration
or intranasal administration (Fernandes and Vanbever, 2009).
Arguably, among these methods, a nose-only aerosol system
would be of highest resemblance to that of in human, such as the
inhalation of aerosolized DNAse Pulmozyme R© for cystic fibrosis
patients. However, the major drawback of this method is the
requirement of highly accurate instruments, an ample amount
of drugs, and a long exposure time (30–45min) that could
subject the infected animals to high level of stress. Intranasal
delivery is one of the most common, and the least intrusive
method for this purpose (Southam et al., 2002; Fernandes and
Vanbever, 2009), hence it was chosen as the drug administration
procedure in our experiment. Despite its simplicity, the downside
of this intranasal delivery is the difficulty in controlling the dose
deposition efficiency, because the drugs have to travel all the way
through the upper respiratory tract before finally reaching the
lungs.
Lung deposition efficiency from intranasal administration of
fluorochrome-tagged PvdQ (PvdQ-VT) at 0 h post-bacterial-
inoculation is in concordance to the study of Eyles and colleagues.
They observed 48 ± 12.1% of radiolabeled 7-µm-diameter
polymer microspheres in the healthy mouse lungs after an
intranasal challenge (Eyles et al., 1999). In our study, the reduced
lung deposition efficiency at the later stage of infection might be
a repercussion of lung function deterioration caused by bacterial
infection, such as a decrease of the inspired air volume as seen
in other studies (Wölbeling et al., 2010, 2011). At 72 h post-
bacterial infection, a shift of deposition toward the left lobe was
observed. This finding is presumably related to the structural
changes experienced by each lobe. However, to explain specific
regional functions of the lungs, further research with a more
elaborate function-related physiology study (e.g., determination
of airspace diameters) is required.
The efficacy of PvdQ was assessed in mouse models with
different levels of infection lethality. PvdQ administered via
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FIGURE 6 | Amounts of (A) CXCL2 and (B) TNF-α in cell-free BAL fluid from the infected animals treated with PBS (black bars) or PvdQ (white bars). The level of both
CXCL2 and TNF-α of PvdQ treatment group was lower in comparison to the PBS-treated group at 24 h post-infection. Three animals were sacrificed from each group
at every time point. The bars represent mean and standard deviation.
an intranasal route during lethal infection resulted in a lower
bacterial load in the lungs, demonstrating a role of PvdQ in
promoting bacterial clearance (Figure 3). Since the delivered
PvdQ is a sub-MIC dose that did not affect bacterial growth
in vitro and in a C. elegans infection model, we strongly believe
that PvdQ does not clear the infection itself but is helping the
immune system by disarming the bacteria in the mouse infection
model. As a result of the lowered bacterial load, survival time
of PvdQ treatment group was increased, in agreement with
other murine studies of AHL-lactonases AiiM (Migiyama et al.,
2013) and SsoPox-I (Hraiech et al., 2014). In addition, our
results also corroborate with the findings from animal studies
of small molecule QSIs, such as furanone, patulin and garlic
extracts (Wu et al., 2004; Bjarnsholt et al., 2005; Rasmussen
et al., 2005). However, some of these QSIs such as patulin and
furanone are known to be toxic for mammals (Hentzer and
Givskov, 2003; Puel et al., 2010). In addition, the small molecule
QSIs having intracellular targets are prone to development of
resistance via upregulated eﬄux pumps (García-Contreras et al.,
2013). The median survival after PvdQ treatment is longer
than shown for the group of animals receiving a deferred
SsoPox-I lactonase treatment (45 h) in the study of Hraiech
and colleagues (Hraiech et al., 2014). Direct comparisons with
the group receiving an immediate treatment is not possible
because the median survival cannot be calculated from their
data as they stopped their observation after 50 h post-bacterial
infection. The fact that our mice eventually were still dying
even though the bacterial load is lower, may be related to
an overwhelming inflammatory response. The high bacterial
load may induce an excess of inflammatory responses that
cannot be counteracted by PvdQ disarming virulence factors
anymore.
In order to perform an extensive analysis of immune
responses, we extended our study with a more thorough
examination during a sublethal infection. The experimental setup
was similar to that of the lethal infection, but with a smaller
bacterial inoculum. Consequently, the sublethal infection was
milder and the defense mechanisms themselves could clear
the infection, resulting in a 1,000-fold lower bacterial CFU in
comparison to the lethal infection. The treatment with PvdQ
in the sublethal P. aeruginosa infection did not lead to a
lower bacterial count in comparison to the PBS-treated group
(Supplementary Figure 4), but resulted in less lung inflammation
(Figures 4, 5) as well as lower levels of CXCL2 and TNF-
α (Figure 6) suggesting that virulence has been suppressed.
High levels of proinflammatory cytokines are observed during
bacterial infection in CF patients, including IL-8 (a human
analog of CXCL2 in mouse) and TNF-α (Richman-Eisenstat,
1996). The high levels of IL-8 and TNF-α in the sputum
positively correlate with clinical symptoms of deterioration in
CF patients and antibiotic treatment resulted in lower levels
of both cytokines (Karpati et al., 2000; Colombo et al., 2005).
Numerous bacterial virulence factors are known to activate
innate immune responses, while others are responsible for tissue
damage during infection. This includes 3-oxo-C12-HSL that
is not only a potent chemoattractant of neutrophils (Karlsson
et al., 2012) but also can induce an inflammatory response by
macrophages (Telford et al., 1998; Thomas et al., 2006). Many
QS-regulated virulence determinants are known for their tissue
destructive properties, among them is elastase that hydrolyses
protein elastin of lung tissue (Van Delden and Iglewski, 1998).
Our observations in the sublethal infection model indicate that
PvdQ treatment may reduce lung inflammation by preventing
the accumulation of 3-oxo-C12-HSL and thereby diminishing the
production of virulence factors that contribute to lung injury.
We observed no difference in the number of inflammatory
cells in BAL fluid from the PBS treatment group, even
though a considerably higher amount of cells was found
at the epithelial tissue of the PBS-treated group (Figure 5).
Extracellular factors of P. aeruginosa such as 3-oxo-C12-HSL
(Tateda et al., 2003), rhamnolipid (Jensen et al., 2007), and
pyocyanin (Allen et al., 2005) potentially induced apoptosis of
the neutrophils that migrated to the alveolar space, reducing
the number of cells in BAL fluid. The dose of 25 ng/g is
presumably sufficient to fully hydrolyze extracellular AHLs in
the lungs. Hence, increasing the PvdQ dose further did not
improve the therapeutic efficacy in both lethal and sublethal
infections.
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Taken together, our study shows that the intranasally
administered PvdQ acylase can act as a therapeutic QQ enzyme to
attenuate P. aeruginosa in a mouse pulmonary infection model.
The inhibition of P. aeruginosa virulence clearly contributed
to bacterial clearance and an improved condition of the lungs.
Hence, PvdQ by itself can be a potential candidate as a part of
the treatment of pulmonary infection. Increasing the shelf-life of
PvdQ is achievable by formulating it into a dry powder that is
suitable for inhalation (Wahjudi et al., 2012). Another interesting
approach is to employ PvdQ in the combination therapy to
increase the efficacy of conventional antibiotics. Therefore, in the
future studies, expanding the therapeutic application of PvdQ
would be of high interest.
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